PT - JOURNAL ARTICLE AU - Yang, Xinxin AU - Wipperman, Matthew F. AU - Nachman, Sharon AU - Sampson, Nicole S. TI - Retrospective feasibility study of <em>Mycobacterium tuberculosis</em> modified lipoprotein as a potential biomarker for TB detection in children AID - 10.1101/2021.03.26.21254411 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.26.21254411 4099 - http://medrxiv.org/content/early/2021/04/04/2021.03.26.21254411.short 4100 - http://medrxiv.org/content/early/2021/04/04/2021.03.26.21254411.full AB - Background Current TB diagnostic methods available have been developed for adults and development efforts have neglected the differences in disease and sampling that occur between adults and children. Diagnostic challenges are even greater in HIV co-infected children and infants.Methods and results We established a sandwich ELISA assay to detect Mycobacterium tuberculosis modified lipoprotein (TLP) ex vivo in plasma. The study population contains plasma samples from 21 patients with active TB and 24 control samples with no TB, collected in the International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) P1041 study. Retrospective analysis was performed and the result demonstrate that TLP level is associated with TB disease.Conclusions Plasma levels of TLP associate with active TB disease in HIV positive subjects and can be used as an indicator for TB detection in children.Competing Interest StatementThis work was partially funded by an STTR to Chronus Pharmaceuticals, Nicole Sampson is President and co-owner. Xinxin Yang was an employee of both Chronus and Stony Brook University. All Intellectual Property is currently owned by Stony Brook University and has not been licensed.Funding StatementResearch reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number U01HL127522, and National Institute of Allergy and Infectious Diseases (NIAID) under award number R41AI136071 to Chronus Pharmaceuticals, Inc with a subcontract to Stony Brook University (NSS) and the National Center for Advancing Translational Sciences under award number TL1TR002386 (MFW). Overall support for the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network was provided by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under Award Numbers UM1AI068632 (IMPAACT LOC), UM1AI068616 (IMPAACT SDMC) and UM1AI106716 (IMPAACT LC), with co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stony Brook University IRB found this work exempt under the NIH Common RuleAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with this work in the manuscript.